Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.
Launched by ASOC. PROF. ERDOĞAN SELÇUK ŞEBER · Feb 18, 2021
Trial Information
Current as of June 13, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Group 1
- • 1. 18 years old and above
- • 2. Having completed two doses of CoronoVac vaccine on time
- • 3. Those with a pathological diagnosis of breast cancer or lung cancer
- • 4. Being the first dose of vaccine during active chemotherapy period
- • 5. Ecog performance score 0-1
- • 6. Patients who signed the informed voluntary consent form
- • Group 2
- • 1. Over 18 years old
- • 2. Ecog performance score is 0-1
- • 3. Those who have completed 2 doses of coronovac vaccine within the recommended period
- • 4. Volunteer who signed the informed consent form
- Exclusion Criteria:
- • For all groups
- • 1. Being confirmed or suspected covid-19 before vaccination
- • 2. Symptomatic covid-19 infection
- • 3. Being addicted to alcohol or drugs
- • 4. Having a fever of 37.8 ° C as a suspect before vaccination
- • 5. Aspleni
About Asoc. Prof. Erdoğan Selçuk şeber
Asoc. Prof. Erdoğan Selçuk Şeber is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With extensive expertise in [specific area of research, if applicable], he leads innovative clinical trials that adhere to the highest standards of ethical and scientific rigor. His collaborative approach engages multidisciplinary teams to explore novel therapeutic strategies, ensuring that trials are designed to yield meaningful insights and contribute to the broader medical community. Through his leadership, Asoc. Prof. Şeber fosters an environment of excellence in clinical investigation, aiming to translate research findings into effective clinical practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tekirdağ, , Turkey
Patients applied
Trial Officials
Erdoğan Selçuk Şeber, Asoc.prof
Study Chair
Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji
Halil Taşkaynatan, Asoc.prof
Principal Investigator
İzmir Özel Ege Şehir Hastanesi
Özkan Alan, MD
Principal Investigator
Tekirdağ Dr. İsmail Fehmi Cumalıoğlu Şehir Hastanesi
Üyesi Sonat Pınar Kara, MD
Principal Investigator
Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, İç Hastalıkları
Aliye Çelikkol, MD
Principal Investigator
Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi Tıbbi Biyokimya ABD,
Okan Avcı, MD
Principal Investigator
Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji
Eyyüp Çavdar, MD
Principal Investigator
Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji
Kubilay Karaboyun, MD
Principal Investigator
Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji
Berna Erdal, DR
Principal Investigator
Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi Mikrobiyoloji ABD
Yakup İriağaç, MD
Study Director
Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials